Coave Therapeutics to Present at Upcoming Conferences
March 27, 2024 07:00 ET
|
Coave Therapeutics
Paris, France, March 27, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces that its management will be attending the following...
Coave Therapeutics Receives Grant from the ALS Association to Advance its CTx-TFEB Program as a Potential Treatment for All Forms of ALS
February 29, 2024 07:00 ET
|
Coave Therapeutics
CTx-TFEB is a novel, targeted genetic medicine approach designed to promote autophagy and reduce the accumulation of toxic protein aggregates in neurons Funding aims to support the progression of...
Coave Therapeutics appoints Leading World Experts to newly formed Scientific Advisory Board dedicated to its Genetic Medicine Delivery Platform
October 12, 2023 07:00 ET
|
Coave Therapeutics
Paris, France, October 12th, 2023– Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces the formation of its new Scientific Advisory Board...
Coave Therapeutics to Present at Upcoming Conferences
September 28, 2023 08:15 ET
|
Coave Therapeutics
Paris, France, September 28, 2023 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces...
Coave Therapeutics Appoints Genetic Medicine Expert Lolita Petit, PhD as Chief Scientific Officer
September 21, 2023 06:00 ET
|
Coave Therapeutics
Paris, France, September 21, 2023 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces...
Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
May 31, 2023 06:00 ET
|
Coave Therapeutics
CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile Positive results from the study to date support preparations for a...
Coave Therapeutics to Participate in Upcoming Conferences
May 17, 2023 03:00 ET
|
Coave Therapeutics
Paris, France, May 17, 2023 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases,...
Coave Therapeutics Demonstrates its Modified coAAV Vectors Outperform AAV9 to Address Neurological Disorders
May 04, 2023 08:00 ET
|
Coave Therapeutics
New data to be presented at ASGCT 2023 Paris, France, May 4, 2023 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS...
Coave Therapeutics to Present at Upcoming Conferences
March 16, 2023 04:00 ET
|
Coave Therapeutics
Paris, France, March 16, 2023 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye...